Lilly's mGlu2/3 Agonist Fails In Phase II For Schizophrenia
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Neither Lilly's novel mGlu2/3 molecule nor its comparator, olanzapine, was more effective than placebo in treating acute schizophrenia in a Phase II study, highlighting the problems inherent in clinical trials for the indication
You may also be interested in...
Last Gasp Or New Life? 2009’s Novel Products Have Blockbuster Potential
After a 2008 NME approval slate that was heavy on modest specialty products, the 2009 user fee calendar offers the potential for a return of the blockbuster
Troubled Biotechs: Intercytex, Vanda, Advanced Life Sciences
With disappointing data from its lead program, the UK’s InterCytex is considering all options, including merger. In the U.S., Vanda is facing shareholder activism while Advanced Life Sciences is in the odd position of not being able to afford good news from FDA.
Solvay's Androgel REMS Proposal May Need More Restrictions - Cmte.
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee